Total Intravenous Anesthesia and Recurrence Free Survival

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Treatments: Anesthetics; Propofol; Sevoflurane

Criteria

Inclusion Criteria:

• Primary esophageal cancer without known extension beyond the esophagus. (i.e. believed to be Tumor Stage 1-3).

• Scheduled for potentially curative esophageal cancer surgery.

• Written informed consent, including willingness to be randomized to intravenous versus volatile anesthesia.

Exclusion Criteria:

• Previous surgery for esophageal cancer (except diagnostic biopsies) Age <18 or >85 years old.

• ASA Physical Status ≥4.

• Any contraindication to propofol or sevoflurane.

• Other cancer not believed by the attending surgeon to be in long-term remission.

• Systemic disease believed by the attending surgeon to present ≥25% two- year mortality.